| Literature DB >> 33283552 |
Vera Silva1, Eva Gil-Martins1, Bárbara Silva1, Carolina Rocha-Pereira1, Maria Emília Sousa2,3, Fernando Remião1, Renata Silva1.
Abstract
Introduction: P-glycoprotein (P-gp) is an important efflux pump responsible for the extruding of many endogenous and exogenous substances out of the cells. P-gp can be modulated by different molecules - including xanthone derivatives - to surpass the multidrug resistance (MDR) phenomenon through P-gp inhibition, or to serve as an antidotal strategy in intoxication scenarios through P-gp induction/activation.Areas covered: This review provides a perspective on P-gp modulators, with particular focus on xanthonic derivatives, highlighting their ability to modulate P-gp expression and/or activity, and the potential impact of these effects on the pharmacokinetics, pharmacodynamics and toxicity of P-gp substrates.Expert opinion: Xanthones, of natural or synthetic origin, are able to modulate P-gp, interfering with its protein synthesis or with its mechanism of action, by decreasing or increasing its efflux capacity. These modulatory effects make the xanthonic scaffold a promising source of new derivatives with therapeutic potential. However, the mechanisms beyond the xanthones-mediated P-gp modulation and the chemical characteristics that make them more potent P-gp inhibitors or inducers/activators are still understudied. Furthermore, a new window of opportunity exists in the neuropathologies field, where xanthonic derivatives with potential to modulate P-gp should be further explored to optimize the prevention/treatment of brain pathologies.Entities:
Keywords: P-glycoprotein; Xanthones; activation; activators; inducers; induction; inhibition; inhibitors; modulation; pharmacokinetics
Year: 2021 PMID: 33283552 DOI: 10.1080/17425255.2021.1861247
Source DB: PubMed Journal: Expert Opin Drug Metab Toxicol ISSN: 1742-5255 Impact factor: 4.481